The aim of this prospective study was to evaluate the clinical and prognostic impact of immunohisto-chemically assessed uPA and PAI-1 in patients with gastric cancer.
Methods
This prospective study analyzed specimens obtained from 105 gastric cancer patients who underwent gastrectomy with extended lymphadenectomy. The immunohistochemical expression of uPA and PAI-1 was studied semiquantitatively in the tumor epithelium and was correlated with the clinicopathological features of each patient.
Results
Univariate analysis revealed no statistically significant association of uPA levels with pT and pN category (p=0.655 and 0.053, respectively), grading (p=0.374), depth of tumor invasion (p=0.665), UICC classification (p=0.21) and the Laurén classification (p=0.578). PAI-1 expression showed no statistically significant correlation with pT, pN and M category (p=0.589, 0.414, and 0.167, respectively), grading (p=0.273), and the Laurén classification (p=0.368). Only the UICC classification was significantly correlated with PAI-1 (p=0.016). Kaplan-Meier analysis revealed no significant association of uPA and PAI-1 with overall survival (p=0.0929 and 0.0870, respectively).
Conclusions
Our results could not verify any prognostic value of uPA and PAI-1 levels in patients with gastric carcinoma. Therefore, the uPA-system as a biologically defined prognostic marker to identify high-risk gastric cancers should be applied with caution. However, considering the number of patients involved and the borderline level of significance observed in this study, a larger number of events may have resulted in significant differences.
ZetterB.R.Angiogenesis and tumor metastasis.Annu Rev Med1998; 49: 407–24.
2.
DanoK., AndreasenP.A., Grondahl-HansenJ., KristensenP., NielsenL.S., SkriverL.Plasminogen activators, tissue degradation, and cancer.Adv Cancer Res1985; 44: 139–266.
3.
AndreasenP.A., KjollerL., ChristensenL., DuffyM.J.The urokinase-type plasminogen activator system in cancer metastasis: a review.Int J Cancer1997; 72: 1–22.
4.
CuferT., VrhovecI., BorstnarS.Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival.Int J Biol Markers2002; 17: 33–41.
5.
DugganC., MaguireT., McDermottE., O'HigginsN., FennellyJ.J., DuffyM.J.Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.Int J Cancer1995; 61: 597–600.
6.
ReillyD., AndreasenP.A., DuffyM.J.Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.Blood Coagul Fibrinolysis1991; 2: 47–50.
7.
CuferT., BorstnarS., VrhovecI.Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.Int J Biol Markers2003; 18: 106–15.
8.
MeoS., DittadiR., PelosoL., GionM.The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.Int J Biol Markers2004; 19: 282–8.
9.
HarbeckN., KrugerA., SinzS.Clinical relevance of the plasminogen activator inhibitor type 1 – a multifaceted proteolytic factor.Onkologie2001; 24: 238–44.
10.
PrechtlA., HarbeckN., ThomssenC.Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer.Int J Biol Markers2000; 15: 73–8.
11.
Grondahl-HansenJ., RalfkiaerE., KirkebyL.T., KristensenP., LundL.R., DanoK.Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.Am J Pathol1991; 138: 111–7.
12.
MiseljicS., GalandiukS., MyersS.D., WittliffJ.L.Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease.J Clin Lab Anal1995; 9: 413–7.
13.
UmeharaY., KimuraT., YoshidaM., ObaN., HaradaY.Relationship between plasminogen activators and stomach carcinoma stage.Acta Oncol1991; 30: 815–8.
14.
HeissM.M., BabicR., AllgayerH.The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.Eur J Surg Oncol1996; 22: 74–7.
15.
ChoJ.Y., ChungH.C., NohS.H., RohJ.K., MinJ.S., KimB.S.High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.Cancer1997; 79: 878–83.
PetersenL.C., LundL.R., NielsenL.S., DanoK., SkriverL.One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.J Biol Chem1988; 263: 11189–95.
18.
HarveyS.R., LawrenceD.D., MadejaJ.M., AbbeyS.J., MarkusG.Secretion of plasminogen activators by human colorectal and gastric tumor explants.Clin Exp Metastasis1988; 6: 431–50.
19.
WilhelmO., HafterR., HenschenA., SchmittM., GraeffH.Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.Blood1990; 75: 1673–8.
20.
EllisV., PykeC., EriksenJ., SolbergH., DanoK.The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.Ann N Y Acad Sci1992; 667: 13–31.
21.
LijnenH.R., SilenceJ., LemmensG., FrederixL., CollenD.Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.Thromb Haemost1998; 79: 1171–6.
22.
Keski-OjaJ., KoliK.Enhanced production of plasminogen activator activity in human and murine keratinocytes by transforming growth factor-beta 1.J Invest Dermatol1992; 99: 193–200.
23.
NaldiniL., TamagnoneL., VignaE.Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.Embo J1992; 11: 4825–33.
24.
OssowskiL., Russo-PayneH., WilsonE.L.Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.Cancer Res1991; 51: 274–81.
25.
RonneE., BehrendtN., EllisV., PlougM., DanoK., Hoyer-HansenG.Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor.FEBS Lett1991; 288: 233–6.
26.
KobayashiH., OhiH., SugimuraM., ShinoharaH., FujiiT., TeraoT.Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.Cancer Res1992; 52: 3610–4.
27.
LookM.P.Pooled analysis of uPA and PAI-1 for prognosis in primary breast cancer patients. EORTC Receptor and Biomarker Study Group.Int J Biol Markers2000; 15: 70–2.
28.
SkriverL., LarssonL.I., KielbergV.Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.J Cell Biol1984; 99: 752–7.
29.
BurtinP., ChavanelG., AndreJ.The plasmin system in human colonic tumors: an immunofluorescence study.Int J Cancer1985; 35: 307–14.
30.
CajotJ.F., KruithofE.K., SchleuningW.D., SordatB., BachmannF.Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.Int J Cancer1986; 38: 719–27.
31.
GrebenschikovN., Geurts-MoespotA., De WitteH.A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.Int J Biol Markers1997; 12: 6–14.
32.
ReuningU., MagdolenV., WilhelmO.Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).Int J Oncol1998; 13: 893–906.
DengG., CurridenS.A., WangS., RosenbergS., LoskutoffD.J.Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?J Cell Biol1996; 134: 1563–71.
35.
OkusaY., IchikuraT., MochizukiH.Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.Cancer1999; 85: 1033–8.
36.
BlasiF.Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system.Thromb Haemost1999; 82: 298–304.
37.
PykeC., KristensenP., RalfkiaerE.Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.Am J Pathol1991; 138: 1059–67.
38.
NekardaH., SchmittM., UlmK.Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.Cancer Res1994; 54: 2900–7.
39.
NekardaH., SiewertJ.R., SchmittM., UlmK.Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.Lancet1994; 343: 117.
40.
HeissM.M., BabicR., AllgayerH.Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.J Clin Oncol1995; 13: 2084–93.
41.
KanekoT., KonnoH., BabaM., TanakaT., NakamuraS.Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.Cancer Sci2003; 94: 43–9.
42.
DuffyM.J., MaguireT.M., McDermottE.W., O'HigginsN.Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.J Surg Oncol1999; 71: 130–5.
43.
AllgayerH., BabicR., GrutznerK.U.Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.Clin Exp Metastasis1998; 16: 62–73.
44.
ItoH., YonemuraY., FujitaH.Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.Virchows Arch1996; 427: 487–96.
45.
Grondahl-HansenJ., ChristensenI.J., RosenquistC.High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res1993; 53: 2513–21.
46.
ReillyD., ChristensenL., DuchM., NolanN., DuffyM.J., AndreasenP.A.Type-1 plasminogen activator inhibitor in human breast carcinomas.Int J Cancer1992; 50: 208–14.
47.
JanickeF., SchmittM., PacheL.Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.Breast Cancer Res Treat1993; 24: 195–208.
48.
DuffyM.J., ReillyD., O'SullivanC., O'HigginsN., FennellyJ.J., AndreasenP.Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.Cancer Res1990; 50: 6827–9.
49.
VassalliJ.D., BaccinoD., BelinD.A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.J Cell Biol1985; 100: 86–92.
50.
CubellisM.V., NolliM.L., CassaniG., BlasiF.Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.J Biol Chem1986; 261: 15819–22.
51.
AppellaE., RobinsonE.A., UllrichS.J.The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.J Biol Chem1987; 262: 4437–40.
52.
HeissM.M., AllgayerH., GruetznerK.U.Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.Nat Med1995; 1: 1035–9.
